Table 5 Effects of mAbs on monocytes and... | American Society of Hematology

Table 5

Effects of mAbs on monocytes and lymphocyte subsets in human whole blood

Stimulation/mAb	B cells	Monocytes	CD56^high NK	CD56^medium NK	NKT cells	T cells	CD69⁺CD56^high NK cells	CD69⁺CD56^medium NK cells	CD69⁺ NKT cells	CD69⁺ T cells
PBS
None	4.72 ± 0.30	0.63 ± 0.06	0.21 ± 0.06	1.88 ± 0.06	3.20 ± 0.79	39.3 ± 3.4	1.51 ± 0.75	2.47 ± 0.34	1.99 ± 0.12	0.98 ± 0.12
Labetuzumab	3.92 ± 0.53	0.69 ± 0.16	0.34 ± 0.21	1.69 ± 0.05	3.52 ± 0.68	37.0 ± 2.1	4.21 ± 2.67	8.83 ± 4.15	3.16 ± 0.71	1.15 ± 0.52
IMMU-114	2.11 ± 0.77*	0.41 ± 0.08*	0.18 ± 0.05	1.90 ± 0.09	3.18 ± 0.38	38.4 ± 1.9	1.96 ± 1.00	2.55 ± 0.52	1.83 ± 0.13	0.76 ± 0.16
Rituximab	1.45 ± 0.32*	0.95 ± 0.04	0.19 ± 0.02	1.84 ± 0.06	3.21 ± 0.18	37.3 ± 1.2	2.83 ± 0.76	4.20 ± 0.82	2.14 ± 0.55	0.83 ± 0.27
PHA
None	3.82 ± 0.56	1.03 ± 0.15	0.19 ± 0.05	1.76 ± 0.02	3.02 ± 0.25	34.9 ± 0.7	2.26 ± 1.14	2.38 ± 0.65	1.84 ± 0.42	0.79 ± 0.09
Labetuzumab	3.51 ± 0.62	1.13 ± 0.07	0.15 ± 0.03	1.60 ± 0.09	2.83 ± 0.30	33.7 ± 0.9	2.14 ± 1.05	4.92 ± 0.47	1.93 ± 0.17	0.83 ± 0.03
IMMU-114	1.94 ± 0.57*	0.46 ± 0.13*	0.22 ± 0.09	1.82 ± 0.02	3.29 ± 0.61	36.8 ± 1.8	3.07 ± 0.64	3.75 ± 0.34	2.56 ± 0.45	1.04 ± 0.40
Rituximab	1.23 ± 0.17*	0.94 ± 0.36	0.22 ± 0.10	1.72 ± 0.09	3.20 ± 0.29	34.5 ± 0.2	3.59 ± 1.45	6.00 ± 2.64	3.21 ± 1.58	1.38 ± 0.80
LPS
None	3.13 ± 0.48	0.26 ± 0.05	0.41 ± 0.09	1.63 ± 0.12	2.88 ± 0.15	34.1 ± 0.4	30.75 ± 9.56	42.58 ± 7.36	10.91 ± 2.65	2.47 ± 0.24
Labetuzumab	3.09 ± 0.21	0.33 ± 0.06	0.30 ± 0.11	1.62 ± 0.03	2.92 ± 0.25	34.9 ± 0.6	14.79 ± 8.96	27.94 ± 11.15	5.57 ± 2.48	1.43 ± 0.36
IMMU-114	0.92 ± 0.17*†	0.18 ± 0.06	0.38 ± 0.22	1.67 ± 0.26	2.81 ± 0.40	34.3 ± 2.2	24.08 ± 22.77	37.02 ± 22.37	11.22 ± 7.94	2.26 ± 0.76
Rituximab	2.47 ± 0.30*	0.32 ± 0.10	0.36 ± 0.07	1.66 ± 0.24	2.90 ± 0.40	35.5 ± 0.6	26.15 ± 12.03	40.79 ± 9.35	10.11 ± 2.16	2.38 ± 0.45

Stimulation/mAb	B cells	Monocytes	CD56^high NK	CD56^medium NK	NKT cells	T cells	CD69⁺CD56^high NK cells	CD69⁺CD56^medium NK cells	CD69⁺ NKT cells	CD69⁺ T cells
PBS
None	4.72 ± 0.30	0.63 ± 0.06	0.21 ± 0.06	1.88 ± 0.06	3.20 ± 0.79	39.3 ± 3.4	1.51 ± 0.75	2.47 ± 0.34	1.99 ± 0.12	0.98 ± 0.12
Labetuzumab	3.92 ± 0.53	0.69 ± 0.16	0.34 ± 0.21	1.69 ± 0.05	3.52 ± 0.68	37.0 ± 2.1	4.21 ± 2.67	8.83 ± 4.15	3.16 ± 0.71	1.15 ± 0.52
IMMU-114	2.11 ± 0.77*	0.41 ± 0.08*	0.18 ± 0.05	1.90 ± 0.09	3.18 ± 0.38	38.4 ± 1.9	1.96 ± 1.00	2.55 ± 0.52	1.83 ± 0.13	0.76 ± 0.16
Rituximab	1.45 ± 0.32*	0.95 ± 0.04	0.19 ± 0.02	1.84 ± 0.06	3.21 ± 0.18	37.3 ± 1.2	2.83 ± 0.76	4.20 ± 0.82	2.14 ± 0.55	0.83 ± 0.27
PHA
None	3.82 ± 0.56	1.03 ± 0.15	0.19 ± 0.05	1.76 ± 0.02	3.02 ± 0.25	34.9 ± 0.7	2.26 ± 1.14	2.38 ± 0.65	1.84 ± 0.42	0.79 ± 0.09
Labetuzumab	3.51 ± 0.62	1.13 ± 0.07	0.15 ± 0.03	1.60 ± 0.09	2.83 ± 0.30	33.7 ± 0.9	2.14 ± 1.05	4.92 ± 0.47	1.93 ± 0.17	0.83 ± 0.03
IMMU-114	1.94 ± 0.57*	0.46 ± 0.13*	0.22 ± 0.09	1.82 ± 0.02	3.29 ± 0.61	36.8 ± 1.8	3.07 ± 0.64	3.75 ± 0.34	2.56 ± 0.45	1.04 ± 0.40
Rituximab	1.23 ± 0.17*	0.94 ± 0.36	0.22 ± 0.10	1.72 ± 0.09	3.20 ± 0.29	34.5 ± 0.2	3.59 ± 1.45	6.00 ± 2.64	3.21 ± 1.58	1.38 ± 0.80
LPS
None	3.13 ± 0.48	0.26 ± 0.05	0.41 ± 0.09	1.63 ± 0.12	2.88 ± 0.15	34.1 ± 0.4	30.75 ± 9.56	42.58 ± 7.36	10.91 ± 2.65	2.47 ± 0.24
Labetuzumab	3.09 ± 0.21	0.33 ± 0.06	0.30 ± 0.11	1.62 ± 0.03	2.92 ± 0.25	34.9 ± 0.6	14.79 ± 8.96	27.94 ± 11.15	5.57 ± 2.48	1.43 ± 0.36
IMMU-114	0.92 ± 0.17*†	0.18 ± 0.06	0.38 ± 0.22	1.67 ± 0.26	2.81 ± 0.40	34.3 ± 2.2	24.08 ± 22.77	37.02 ± 22.37	11.22 ± 7.94	2.26 ± 0.76
Rituximab	2.47 ± 0.30*	0.32 ± 0.10	0.36 ± 0.07	1.66 ± 0.24	2.90 ± 0.40	35.5 ± 0.6	26.15 ± 12.03	40.79 ± 9.35	10.11 ± 2.16	2.38 ± 0.45

B cells, monocytes, CD56^high and CD56^medium NK cells, NKT cells, and T cells were gated according to the strategy described in supplemental Figure 1. The percentages of these cell subsets in nucleated cells are shown. Data are representative of 4 blood donors. Activated CD56^high NK cells, CD56^medium NK cells, NKT cells, and T cells are the percentages of CD69⁺ cells in each of these cell subsets.

Statistically significant (P < .05) decreases of more than 20% vs both untreated and control mAb (labetuzumab) treatment.

†

Statistically significant (P < .05) difference between IMMU-114 and rituximab.

View Large

This Feature Is Available To Subscribers Only